Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Keith Kaye

General ID · RU

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Erin Bonura

General ID · OHSU

View

Dr. Nizar Wehbi

General ID

View

Dr. Robert Schooley

General ID · UCSD

View

Dr. Priya Nori

General ID · MMC

View

Dr. Jan Patterson

General ID · UTHSCSA

View

Dr. Kavita Bhavan

General ID · Dallas County Hospital District

View

Dr. John Goldman

General ID · UPMC Central PA

View

Dr. Gonzalo Bearman

General ID · Medical College of Virginia

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Health Economic Analysis of the AMBITION Protocol for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis in the United States.

    Sep 17, 2026DOI: 10.1093/cid/ciag485Journal ArticleCID

    Written by: Devin C ClarkJosh BanerjeeRachel BadenCharles CoffeyKusha DavarSarah FrelingReid GoodmanAmytis TowfighiBrad Spellberg

    Find these authors on Roon

    DC
    Dr. Devin Clark
    General ID · LAC+USC

    Summary

    BACKGROUND: Current guideline-compliant management of cryptococcal meningitis (CM), comprised of lipid-based amphotericin (3-5 mg/kg/day) and flucytosine (100 mg/kg/day) for a minimum of 14 days, is associated with significant costs to both the hospital and insurance payor. Recently published studies have found comparable patient outcomes with the cheaper and better tolerated AMBITION protocol (single-dose liposomal amphotericin with 2 weeks of fluconazole and flucytosine).METHODS: This retrospective, economic evaluation analyzed costs associated with the AMBITION protocol versus guideline-compliant care for patients with human immunodeficiency virus (HIV)-associated CM at a large, academic, public US hospital between August 2020 and July 2024.RESULTS: Treatment of 34 patients with the AMBITION protocol compared to 26 control patients net saved the hospital $399 704 ($11 756 per patient), calculated as variable costs saved minus revenue lost. Cost savings were experienced across all insurance types encountered; however, there were no patients with commercial insurance. In order to accurately model patients who develop CM, we obtained data on the nationwide payor mix for patients with advanced HIV, which still showed net hospital savings, though of smaller magnitude due to lost commercial insurance payments. From an insurance payor perspective, modeling demonstrated cost savings across payor mixes.CONCLUSIONS: In this economic evaluation study, the AMBITION protocol was associated with both hospital and payor savings. These findings provide further support for adoption of the AMBITION protocol for treatment of CM in the United States.
    DCDr. Devin Clark

    Dr. Devin Clark

    Infectious Disease · General Infectious Disease
    LAC+USC Medical Center
    devin